Drugs cut kidney failure risk in Lupus

[Guest guest]

The Lupus Site

Site Updates Lupus News Contact

Message Boards

Chat Room

Lupus store

The Lupus Book(UK customers)

powered by FreeFind

Drugs Cut Kidney Failure Risk in Lupus - Study

BOSTON (Reuters) - Patients with lupus have a better chance of preventing kidney failure if they start taking one of two drugs which suppress the immune system, researchers reported on Wednesday.

About 1.4 million Americans have lupus, a chronic disease in which the immune system can confuse healthy and foreign tissues and sometimes attacks both. Roughly 780,000 lupus sufferers have kidney disease.

, president of the Lupus Foundation of America, said patients have been desperate for better therapies with fewer side effects. "Patients are thrilled," she told Reuters.

A study of 59 volunteers, published in this week's New England Journal of Medicine (news - web sites), found that the conventional treatment -- injections of the drug cyclophosphamide -- prevented a relapse in 43 percent of the cases.

By comparison, one of the drugs found to be effective, azathioprine, worked about 57 percent of the time. The other drug, mycophenolate mofetil, was effective in about 77 percent of the volunteers.

The research team, led by Contreras of the University of Miami, said there were not enough people in the study to determine whether mycophenolate mofetil, marketed as CellCept by Roche, was actually better than azathioprine, sold by several companies. Salix Pharmaceuticals Ltd. sells azathioprine under the name Azasan.

An editorial in the Journal said both drugs "are good options for maintenance therapy" in patients whose lupus was damaging their kidneys.

The two drugs tend to have fewer side effects than cyclophosphamide and can be given by mouth.

The Contreras team cautioned the study did not look at children or patients with mild forms of lupus-related kidney problems.

said she was particularly encouraged by the data for mycophenolate mofetil, which she said seemed to be the best for long-term treatment. But she said a larger study was needed to confirm the findings.

Recommend this site to your friends

Visit our Message Boards

< Previous - Refresh - Next >

Read our privacy policy - Advertise - Sitemap © Copyright The Lupus Site 1997-2004None of my material can be used on any other site, or in any other form, without prior permission from the author. However feel free to link to my site from yours. The Lupus Site is affiliated with Lupus UK through the Lancashire & Cheshire Regional Group.The information on this page is only for general advice. No responsibility can be taken for anything that happens as a result of following or ignoring advice on this site.